Dalton Lisa 4

Accession 0000899243-19-029452

CIK 0001609351other

Filed

Dec 16, 7:00 PM ET

Accepted

Dec 17, 4:54 PM ET

Size

21.3 KB

Accession

0000899243-19-029452

Form 4

Period: 2019-12-17

Head of Human Resources

Transactions

Disposition to Issuer
Stock Option (Right to Buy)
2019-12-17−30,000→ 0 total
Exercise: $40.44Exp: 2026-01-05→ Common Stock (30,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-12-17−19,951→ 0 total
Exercise: $3.45Exp: 2024-08-10→ Common Stock (19,951 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-12-17−19,500→ 0 total
Exercise: $56.17Exp: 2027-01-17→ Common Stock (19,500 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-12-17−28,389→ 0 total
Exercise: $68.45Exp: 2025-03-15→ Common Stock (28,389 underlying)
Disposition from Tender
Common Stock
2019-12-17$114.50/sh−4,134$473,343→ 0 total
Disposition to Issuer
Stock Option (Right to Buy)
2019-12-17−35,000→ 0 total
Exercise: $42.73Exp: 2029-01-15→ Common Stock (35,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-12-17−28,000→ 0 total
Exercise: $50.55Exp: 2028-01-17→ Common Stock (28,000 underlying)
Disposition to Issuer
Restricted Stock Units
2019-12-17−20,325→ 0 total
Exercise: $0.00→ Common Stock (20,325 underlying)

Footnotes (3)

[F1]Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn.
[F2]Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
[F3]Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings).

Documents

1 file

Spark Therapeutics, Inc.

CIK 0001609351

Entity typeother